# OnCo record mds-lower-risk (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/mds-lower-risk/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "mds-lower-risk" ;
  schema:name "Lower-risk myelodysplastic syndromes"@en ;
  schema:alternateName "Low-risk MDS"@en, "IPSS-R very low, low and intermediate MDS"@en, "Lower-risk myelodysplastic neoplasms"@en, "Transfusion-dependent lower-risk MDS"@en ;
  schema:description "Lower-risk myelodysplastic syndromes rarely turn into leukaemia quickly; the problem is anaemia and the transfusions it demands. Erythropoietin, then luspatercept (COMMANDS) and the telomerase blocker imetelstat (IMerge), free many patients from transfusions for months or years, and lenalidomide does the same for the del(5q) subtype."@en ;
  schema:url <https://onco.cc/cancers/mds-lower-risk/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Myelodysplastic_syndrome> ;
  schema:citation <https://en.wikipedia.org/wiki/Myelodysplastic_syndrome>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1446> ;
  onco:tag "subtype-page" ;
  onco:technologies <https://onco.cc/technologies/transfusion-support/> ;
  onco:terms <https://onco.cc/terms/anaemia/>, <https://onco.cc/terms/staging-systems/>, <https://onco.cc/terms/ageing-tissue-field-theory/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-commands-luspatercept-mds-lancet-2023/>, <https://onco.cc/key-papers/paper-imerge-imetelstat-mds-lancet-2024/> ;
  onco:pipeline <https://onco.cc/drugs/luspatercept/>, <https://onco.cc/drugs/imetelstat/>, <https://onco.cc/trials/nct06499285/>, <https://onco.cc/trials/nct05308264/>, <https://onco.cc/trials/nct06243458/>, <https://onco.cc/trials/nct05320198/> ;
  onco:standardOfCare <https://onco.cc/technologies/transfusion-support/>, <https://onco.cc/drugs/luspatercept/>, <https://onco.cc/drugs/epoetin-alfa/>, <https://onco.cc/drugs/darbepoetin-alfa/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/imetelstat/>, <https://onco.cc/drugs/luspatercept/>, <https://onco.cc/drugs/azacitidine/>, <https://onco.cc/trials/nct06499285/>, <https://onco.cc/trials/nct05308264/>, <https://onco.cc/trials/nct06243458/>, <https://onco.cc/technologies/transfusion-support/>, <https://onco.cc/technologies/g-csf-growth-factors/> .